Search for drugs:

TRIPTORELIN PAMOATE


DIR Classification


Classification:Ambiguous
Severity Score:1.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

  • WARNINGS AND PRECAUTIONS
  • Effect on QT/QTc Interval
  • Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

Postmarketing Surveillance

Contingency Table:

Current Drug
Other Drugs
QT Prolongation
6
24086
Other ADRs
5036
38376551

Odds Ratio = 1.899

Drug Property Information



ATC Code(s):
  • L02AE04 - triptorelin pamoate
    • L02AE - Gonadotropin releasing hormone analogues
    • L02A - HORMONES AND RELATED AGENTS
    • L02 - ENDOCRINE THERAPY
    • L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:TRIPTORELIN PAMOATE
Active Ingredient UNII:08AN7WA2G0
Drugbank ID:DB06825
PubChem Compound:25074470
CTD ID: D017329
PharmGKB:
CAS Number:57773-63-4
Dosage Form(s):kit
Route(s) Of Administrator:intramuscular
Daily Dose:
  • 0.134 mg/day L02AE04
Chemical Structure:
SMILE Code:
CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O

Reference

N/A

Disclaimer:

The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.

Any mention of commercial products is for clarification and not intended as endorsement.